Clinical Trial Update: A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing Acetylcysteine 2% oral solution with Fluimucil 2% oral solution has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Tract Infection

Drugs mentioned

• Acetylcysteine 2% oral solution (GSK) (acetylcysteine)
• Fluimucil 2% oral solution (acetylcysteine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Respiratory Tract | Phase 1 | Status: COMPLETED